Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
realestateasia1d
Singapore strata retail market dominated by deals under S$4m in H2 2024
The strata retail market remained muted in the second half of 2024, with a slight decline of 1.3% in total sales value to S$214.8 million from S$217.5 million i ...
AZoNano3d
Non-Invasive Particle Size Monitoring of Polymer-Based Vectors for Cell Transfection in Process Vessels
Accurate monitoring of particle size and growth is essential to ensure scalability in the development of transfection vectors ...